Schwartzhein5460

Z Iurium Wiki

Verze z 25. 9. 2024, 16:27, kterou vytvořil Schwartzhein5460 (diskuse | příspěvky) (Založena nová stránka s textem „Objective Late life negative affect (NA) often co-occurs with poor cognitive function (CF); however, very little is known about the mechanism of the relati…“)
(rozdíl) ← Starší verze | zobrazit aktuální verzi (rozdíl) | Novější verze → (rozdíl)

Objective Late life negative affect (NA) often co-occurs with poor cognitive function (CF); however, very little is known about the mechanism of the relationship between them. We examined the longitudinal relationship between NA and CF over a 12-year period and the effects of several related risk factors in a general sample. Methods Five waves of data on Chinese Longitudinal Healthy Longevity Survey (CLHLS) were collected from a total of 1,314 elderly Chinese, aged 60 and over. A parallel process latent growth curve model with two time-invariant covariates and seven time-varying covariates was used to demonstrate the joint trajectories of NA and CF to assess their related factors in the elderly during a 12-year period. Results Significant association of negative affect and cognitive decline was found at baseline and over time for our sample. ABT-199 Poorer initial cognitive performance predicted a faster increase in negative affect over time. Being female was associated with worse initial performance and a faster rate of deterioration of NA and CF. Regular exercise, married status, social activities, and Mahjong playing were associated with slower rates of negative affect increase and cognitive decline. Conclusion These findings demonstrated that the late life negative affect co-occurs with cognitive decline and negative affect might be a mutative mental reaction to cognitive dysfunction. Gender difference, exercise benefit, and the "need to belong" effect were observed over time, highlighting the importance of exercise and socialization for older females.Background With the aging phenomenon, there is growing interest in developing effective strategies to counteract dynapenia, the age-related loss of muscle strength. The positive effect of progressive resistance training on muscle strength is well known, however, the effect of nutritional supplementation or its synergistic effect along with exercise on muscle strength is not a consensus in the literature, especially in populations with low protein intake. Methods We analyzed the muscle strength (handgrip strength and sit-to-stand test), muscle mass, body mass index, insulin resistance, and physical function (gait speed, timed up & go test, and single-leg-stance test) of 69 dynapenic older adults with low protein intake, before and after the intervention period of three months. The participants were randomly allocated into four groups resistance training, supplementation, resistance training plus supplementation, and control. Results There was a significant group x time interaction on the following outcome measures handgrip strength (p less then 0.001), gait speed (p = 0.023), and sit-to-stand test (p less then 0.001). Considering the outcomes that showed a significant difference between and within groups, only the resistance training group and the resistance training plus supplementation group showed a large effect size in handgrip strength, gait speed, and sit-to-stand test, whereas the supplementation group showed a moderate effect size in gait speed. After the intervention period, there was no difference between the resistance training and the resistance training plus supplementation groups. Conclusion This study reinforces the value of resistance training in improving muscle strength. The nutritional supplementation added no further benefits in this specific population. Registration number at the Brazilian registry of clinical trials RBR-4HRQJF.Silica-lipid hybrid (SLH) microparticles are a solidified lipid-based drug delivery system under investigation for their aptitude to enhance the oral bioavailability of poorly water-soluble drugs. The cholesterol-lowering agent, simvastatin (SIM), is poorly water-soluble and undergoes extensive first pass metabolism, resulting in a low oral bioavailability of approximately 5%. Hence, the current pre-clinical studies investigated the application of SLH technology to SIM with a supersaturation approach, aiming to enhance bioavailability and drug loading capacity. Additionally, the effect of silica was explored by evaluating the performance of SLH fabricated with silica of different particle geometries. SLH microparticles with supersaturated SIM loading levels ranging from 100% to 400% above the equilibrium solubility were successfully fabricated using either Aerosil® 300 or Syloid® 244 silica. All SLH formulations existed as white free-flowing powders, consisting of spherical porous microparticles for Aerosil® 300, and aggregated irregular microparticles for Syloid® 244. During in vitro dissolution in pH 7.0 media, the SLH formulations performed up to 4.4-fold greater than pure SIM powder. Furthermore, in vivo oral pharmacokinetics in male Sprague-Dawley rats revealed that the SLH formulations enhanced the oral bioavailability of SIM up to 6.1-fold and 2.9-fold, in comparison to pure SIM powder and a commercially available formulation (Simvastatin Sandoz®), respectively. The greatest in vivo performance enhancement was observed for the SLH formulation manufactured with Syloid® 244 silica with a supersaturation level of 200%. SLH technology demonstrated to be a successful formulation strategy to significantly improve the oral bioavailability of SIM in rodents and therefore, has a strong potential to also improve the oral bioavailability of SIM in humans.Background There aren't many reported skin changes associated with teriflunomide use in patients with multiple sclerosis (MS) mm Only one life-threatening gross skin change has been reported so far; a patient with toxic epidermal necrolysis. There are also a few case reports about cutaneous adverse effects of teriflunomide, such as eczema, rash and palmar pustular psoriasis. Methods We herein report the first case of bullous drug reaction in a patient receiving teriflunomide treatment. Results A 55-year-old women with relapsing multiple sclerosis (RMS) was diagnosed teriflunomide induced bullous pemphigoid as it was detected in the first three months following the initiation of therapy. It is fully recovered after withdrawal of teriflunomide, in combination with systemic steroid treatment. Discussion We report the first case of bullous drug reaction associated with teriflunomide. Multiple drugs have been implicated in the pathogenesis of the disease so far. It is important to point out some immunosuppressants may trigger autoimmune diseases like bullous pemphigoid.

Autoři článku: Schwartzhein5460 (Udsen Meier)